Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2002-12-27
2010-02-16
Raghu, Ganapathirama (Department: 1652)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S017400, C435S193000, C435S320100, C435S069100, C435S006120, C530S327000, C530S330000, C530S388260, C536S023200
Reexamination Certificate
active
07662769
ABSTRACT:
The present invention provides a peptide or protein having a neovascularization action and containing a basic amino acid cluster region of β1,6-N-acetylglucosaminyltransferase, a neovascularization accelerator containing the above-mentioned peptide or protein, a method of screening an inhibition substance for the above-mentioned peptide or protein, and a neovascularization inhibitor containing this inhibition substance.
REFERENCES:
patent: 6191113 (2001-02-01), Nakahara et al.
patent: 6932973 (2005-08-01), Barritault et al.
patent: 585109 (1994-03-01), None
patent: 9-84582 (1997-03-01), None
patent: 10-137000 (1998-05-01), None
patent: WO-01/27136 (2001-04-01), None
patent: WO-02/34767 (2002-05-01), None
patent: WO-02/34767 (2002-05-01), None
Tischer et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing, J Biol Chem. Jun. 25, 1991;266(18):11947-54.
Kisselev L., Polypeptide release factors in prokaryotes and eukaryotes: same function, different structure. Structure, 2002, vol. 10: 8-9.
Wishart et al., A single mutation converts a novel phosphotyrosine binding domain into a dual-specificity phosphatase. J. Biol. Chem., 1995, vol. 270(45): 26782-26785.
Witkowski et al., Conversion of b-ketoacyl synthase to a malonyl decarboxylase by replacemnt of the active-site cysteine with glutamine. Biochemistry, 1999, vol. 38: 11643-11650.
Murata K. et al., “Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis,” Clin. Cancer Res., 2000, vol. 6, No. 5, pp. 1772-1777.
Sasai K. et al., “The critical role of the stem region as a finctional domain responsible for the oligomerization and golgi localization of N-acetylglucosaminyltransferase V,” J. Biol. Chem., 2001, vol. 276, No. 1, pp. 759-765.
Wolfe M. S. et al., “A substrate-based difluoro ketone selectively inhibits Alzheimer's Y-secretase activity,” J.Med.Chem., 1998, vol. 41, pp. 6-9.
Taniguchi N. et al., “Implication of N-acetylglucosaminyltransferases III and V in cancer: gene regulation and signaling mechanism,” Biochemica et Biophysica Acta 1999, vol. 1455, pp. 287-300.
Saito T. et al., “A secreted type of β1,6-N-acetylglucosaminyltransferase V (GnT-V) induces tumor angiogenesis without mediation og glycosylation,” J.Biol.Chem., 2002, vol. 277, No. 19, pp. 17002-17008.
Taniguchi, Naoyuki et al., “Implication of GnT-V in Cancer Metastasis: A Glycomic Approach for Identification of a Target Protein and Its Unique Function as an Angiogenic Cofactor,”Glycoconjugate JournalNov.-Dec., vol. 18, Nos. 11-12, Nov. 2001, pp. 859-865.
Daniel, Paris et al., “Inhibition of Angiogenesis and Tumor Growth by Beta and Gamma-Secretase Inhibitors,”European Journal of Pharmacology514(1): 1-15, May 2005.
Barillari et al., “The Basic Residues of Placenta Growth Factor Type 2 Retrieve Sequestered Angiogenic Factors into a Soluble Form,” American Journal of Pathology, vol. 152, No. 5, May 1998, pp. 1161-1166, American Society for Investigative Pathology, Bethesda, MD.
Miyoshi Eiji
Saito Takashi
Taniguchi Naoyuki
Drinker Biddle & Reath LLP
Raghu Ganapathirama
Suntory Holdings Limited
LandOfFree
Glycosyltransferase GnT-V having neovascularization action does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycosyltransferase GnT-V having neovascularization action, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycosyltransferase GnT-V having neovascularization action will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4211966